{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T02:05:30Z","timestamp":1782093930364,"version":"3.54.5"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1097\/fpc.0000000000000097","type":"journal-article","created":{"date-parts":[[2014,11,7]],"date-time":"2014-11-07T22:37:13Z","timestamp":1415399833000},"page":"1-7","source":"Crossref","is-referenced-by-count":19,"title":["Copy number variability analysis of pharmacogenes in patients with lymphoma, leukemia, hepatocellular, and lung carcinoma using The Cancer Genome Atlas data"],"prefix":"10.1097","volume":"25","author":[{"given":"In-Wha","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayoung","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myeong Gyu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therasa","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Mi","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210213","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev.med.56.082103.104724","article-title":"Pharmacogenomics and individualized drug therapy.","volume":"57","author":"Eichelbaum","year":"2006","journal-title":"Annu Rev Med"},{"key":"R2-1-20210213","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1056\/NEJMra020526","article-title":"Pharmacogenomics - drug disposition, drug targets, and side effects.","volume":"348","author":"Evans","year":"2003","journal-title":"N Engl J Med"},{"key":"R3-1-20210213","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1126\/science.286.5439.487","article-title":"Pharmacogenomics: translating functional genomics into rational therapeutics.","volume":"286","author":"Evans","year":"1999","journal-title":"Science"},{"key":"R4-1-20210213","first-page":"1217","article-title":"Drug-metabolism research challenges in the new millennium: individual variability in drug therapy and drug safety.","volume":"26","author":"Lu","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"R5-1-20210213","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/S0140-6736(00)03167-6","article-title":"Pharmacogenetics and adverse drug reactions.","volume":"356","author":"Meyer","year":"2000","journal-title":"Lancet"},{"key":"R6-1-20210213","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/ng1696","article-title":"International HapMap Consortium. Common deletion polymorphisms in the human genome.","volume":"38","author":"McCarroll","year":"2006","journal-title":"Nat Genet"},{"key":"R7-1-20210213","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/jmg.2004.029637","article-title":"Detection of chromosomal imbalances in children with idiopathic mental retardation by array based comparative genomic hybridisation (array-CGH).","volume":"42","author":"Schoumans","year":"2005","journal-title":"J Med Genet"},{"key":"R8-1-20210213","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nature08979","article-title":"Wellcome Trust Case Control Consortium. Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls.","volume":"464","author":"Craddock","year":"2010","journal-title":"Nature"},{"key":"R9-1-20210213","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000184709","article-title":"CNVs of human genes and their implication in pharmacogenetics.","volume":"123","author":"Johansson","year":"2008","journal-title":"Cytogenet Genome Res"},{"key":"R10-1-20210213","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/nature05329","article-title":". Global variation in copy number in the human genome.","volume":"444","author":"Redon","year":"2006","journal-title":"Nature"},{"key":"R11-1-20210213","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/humu.20815","article-title":". Somatic mosaicism for copy number variation in differentiated human tissues.","volume":"29","author":"Piotrowski","year":"2008","journal-title":"Hum Mutat"},{"key":"R12-1-20210213","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1371\/journal.pgen.0010049","article-title":"Genomic disorders: molecular mechanisms for rearrangements and conveyed phenotypes.","volume":"1","author":"Lupski","year":"2005","journal-title":"PLoS Genet"},{"key":"R13-1-20210213","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrg2593","article-title":"Mechanisms of change in gene copy number.","volume":"10","author":"Hastings","year":"2009","journal-title":"Nat Rev Genet"},{"key":"R14-1-20210213","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2217\/pgs.11.135","article-title":"CYP2D6, SULT1A1 and UGT2B17 copy number variation: quantitative detection by multiplex PCR.","volume":"13","author":"Gaedigk","year":"2012","journal-title":"Pharmacogenomics"},{"key":"R15-1-20210213","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/hmg\/ddl468","article-title":". Human SULT1A1 gene: copy number differences and functional implications.","volume":"16","author":"Hebbring","year":"2007","journal-title":"Hum Mol Genet"},{"key":"R16-1-20210213","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1093\/hmg\/ddn345","article-title":". Population-specific GSTM1 copy number variation.","volume":"18","author":"Huang","year":"2009","journal-title":"Hum Mol Genet"},{"key":"R17-1-20210213","doi-asserted-by":"crossref","first-page":"534","DOI":"10.3109\/09540261.2013.825581","article-title":"Complexities of CYP2D6 gene analysis and interpretation.","volume":"25","author":"Gaedigk","year":"2013","journal-title":"Int Rev Psychiatry"},{"key":"R18-1-20210213","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.tpj.6500285","article-title":"Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity.","volume":"5","author":"Ingelman-Sundberg","year":"2005","journal-title":"Pharmacogenomics J"},{"key":"R19-1-20210213","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.molmed.2011.01.007","article-title":"Copy number variants in pharmacogenetic genes.","volume":"17","author":"He","year":"2011","journal-title":"Trends Mol Med"},{"key":"R21-1-20210213","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/ng.2764","article-title":"Cancer Genome Atlas Research Network. The Cancer Genome Atlas Pan-Cancer analysis project.","volume":"45","author":"Weinstein","year":"2013","journal-title":"Nat Genet"},{"key":"R22-1-20210213","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/jhg.2013.42","article-title":"Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity.","volume":"58","author":"Hertz","year":"2013","journal-title":"J Hum Genet"},{"key":"R25-1-20210213","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/clpt.2012.96","article-title":". Pharmacogenomics knowledge for personalized medicine.","volume":"92","author":"Whirl-Carrillo","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"R28-1-20210213","doi-asserted-by":"crossref","first-page":"e7752","DOI":"10.1371\/journal.pone.0007752","article-title":"Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations.","volume":"4","author":"Brennan","year":"2009","journal-title":"PLoS One"},{"key":"R30-1-20210213","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":". The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"R31-1-20210213","doi-asserted-by":"crossref","first-page":"l1","DOI":"10.1126\/scisignal.2004088","article-title":". Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"R32-1-20210213","doi-asserted-by":"crossref","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","article-title":"GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers.","volume":"12","author":"Mermel","year":"2011","journal-title":"Genome Biol"},{"key":"R33-1-20210213","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":". Cytoscape: a software environment for integrated models of biomolecular interaction networks.","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res"},{"key":"R34-1-20210213","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s11033-010-0221-0","article-title":"GSTT1 and GSTM1 gene polymorphisms in European and African populations.","volume":"38","author":"Piacentini","year":"2011","journal-title":"Mol Biol Rep"},{"key":"R35-1-20210213","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/tpj.2012.48","article-title":"Multi-ethnic cytochrome-P450 copy number profiling: novel pharmacogenetic alleles and mechanism of copy number variation formation.","volume":"13","author":"Martis","year":"2013","journal-title":"Pharmacogenomics J"},{"key":"R36-1-20210213","first-page":"579","article-title":"The influence of genetic RFC1, MS and MTHFR polymorphisms on the risk of acute lymphoblastic leukemia relapse in children and the adverse effects of methotrexate.","volume":"22","author":"Niedzielska","year":"2013","journal-title":"Adv Clin Exp Med"},{"key":"R37-1-20210213","first-page":"8972","article-title":"SLC28 genes and concentrative nucleoside transporter (CNT) proteins.","volume":"387-","author":"Pastor-Anglada","year":"2008","journal-title":"Xenobiotica"},{"key":"R38-1-20210213","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/jcb.22481","article-title":"Pathology and biology associated with the fragile FHIT gene and gene product.","volume":"109","author":"Saldivar","year":"2010","journal-title":"J Cell Biochem"},{"key":"R39-1-20210213","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.molmed.2006.11.006","article-title":"WW domain-containing oxidoreductase: a candidate tumor suppressor.","volume":"13","author":"Chang","year":"2007","journal-title":"Trends Mol Med"},{"key":"R40-1-20210213","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1159\/000077515","article-title":"Comparative genomic hybridization (CGH): ten years of substantial progress in human solid tumor molecular cytogenetics.","volume":"104","author":"Gebhart","year":"2004","journal-title":"Cytogenet Genome Res"},{"key":"R41-1-20210213","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10911-009-9109-9","article-title":"ABC transporters, drug resistance, and cancer stem cells.","volume":"14","author":"Dean","year":"2009","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"R42-1-20210213","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10555-007-9046-2","article-title":"Human reduced folate carrier: translation of basic biology to cancer etiology and therapy.","volume":"26","author":"Matherly","year":"2007","journal-title":"Cancer Metastasis Rev"},{"key":"R43-1-20210213","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1124\/jpet.111.190561","article-title":"Human organic cation transporter 1 is expressed in lymphoma cells and increases susceptibility to irinotecan and paclitaxel.","volume":"341","author":"Gupta","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"R44-1-20210213","doi-asserted-by":"crossref","first-page":"835","DOI":"10.2217\/pgs.13.52","article-title":"Pharmacogenetics in clinical practice: how far have we come and where are we going P","volume":"14","author":"Johnson","year":"2013","journal-title":"harmacogenomics"},{"key":"R45-1-20210213","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1038\/sj.bjc.6604721","article-title":"Emerging ethnic differences in lung cancer therapy.","volume":"99","author":"Sekine","year":"2008","journal-title":"Br J Cancer"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000097","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T21:38:06Z","timestamp":1717537086000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201501000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000097","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]}}}